ASMANEX is the first and only once-daily inhaled corticosteroid inhaler
approved for children as young as age 4
KENILWORTH, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) announced today that ASMANEX(R) TWISTHALER(R) 110
mcg (mometasone furoate inhalation powder) is now available in pharmacies
nationwide. ASMANEX is indicated for the maintenance treatment of asthma as
prophylactic therapy in patients four years of age and older, and is the
first and only once-daily inhaled corticosteroid inhaler approved for this
use in children as young as 4. ASMANEX was approved for children ages 4 to
11 by the U.S. Food and Drug Administration (FDA) in February 2008. It is
not indicated for the relief of sudden asthma symptoms or in children less
than 4 years of age.
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/asmanex/34590/
ASMANEX provides physicians with a new treatment option to help manage children's asthma as back-to-school season approaches. Studies show that asthma attacks increase in the back-to-school months, and that asthma emergency room and hospitalization rates spike in September.(1) With asthma affecting more than one child in every 20 in the United States(2), physicians need to help parents and their children be prepared to face the obstacles of managing asthma symptoms during the new school year.
"In my practice, I see an increase in pediatric asthma patients this
time of year as children return to school and become exposed to a new
environment with new allergens or irritants that may aggravate their
symptoms," said Kevin R. Murphy, M.D., board certifi
|SOURCE Schering-Plough Corporation|
Copyright©2008 PR Newswire.
All rights reserved